-
Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound®
-
Zepbound patients can access all doses in either multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299, available by prescription now through LillyDirect*
INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and healthcare providers can select the option that best fits individual needs, preferences, and circumstances. Patients, with a valid prescription, opting for self-pay through LillyDirect®, can receive all doses of Zepbound in a KwikPen or single dose vial, starting at $299 per month for the 2.5 mg dose.1,2
"Zepbound is the #1 prescribed injectable obesity‑management medication,3 helping adults achieve meaningful and clinically proven weight loss, on average, up to 50 pounds as seen in SURMOUNT-5," said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities. "As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines."
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect,4 which offers self-pay pricing at a 50% or greater discount compared to the list price of other incretin (GLP-1) medicines for obesity. One out of every three new patients starting a branded weight management medication was prescribed Zepbound self-pay vials in 2025,5 reflecting strong demand for this innovative access model and Lilly's commitment to supporting patients with obesity.
"After trying so many times to lose weight over the years, I'm grateful I talked to my doctor about Zepbound," said Jacob M., Zepbound patient and LillyDirect customer. "Along with diet and exercise, Zepbound has helped me make real, lasting progress. And LillyDirect made getting the medicine simple, from filling my prescription to home delivery. I feel supported at every step of my weight loss journey."
The demand for Zepbound highlights its strong efficacy profile. In the SURMOUNT-1 trial, adults taking Zepbound 15 mg lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% with placebo. In the SURMOUNT-5 open-label study, people who took Zepbound on average lost 50 lbs (20.2% weight loss) compared to people who took injectable Wegovy and on average lost 33 lbs (13.7% weight loss). See additional data below. To learn more about Zepbound and KwikPen, visit Lilly.com/lillydirect/medicines/zepbound?device=kwikpen.
Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known whether Zepbound is safe and effective for use in children.
Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg doses. The 2.5 mg is a starting dose and not an approved maintenance dose. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg injected subcutaneously once per week for weight reduction and long-term maintenance. The recommended maintenance doses are 10 mg or 15 mg for OSA.
Individual results vary. Zepbound is not for cosmetic weight loss. Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath. If you have any of these symptoms, tell your health care provider. Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.
About Zepbound (tirzepatide) injection
Zepbound is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.
About SURMOUNT-1
Throughout the 72 week clinical trial, people who took Zepbound sustained weight loss—whether taking the 5 mg, 10 mg, or 15 mg dose along with diet and exercise. In a 72-week study of adults without diabetes, average weight loss was 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, 20.9% (48 lbs) for 15 mg, and 3.1% (7 lbs) for placebo. Average starting weights were 226.8 lbs for 5 mg, 233.3 lbs for 10 mg, 232.8 lbs for 15 mg, and 231.0 lbs for placebo.
About SURMOUNT-5
SURMOUNT-5 was a 72-week, multi-center, randomized, open-label, Phase 3b trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with injectable Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes. Data collected in a less rigorous study so findings are less certain. Factors beyond studied medications may have contributed to weight loss. In the 72-week study participants on Zepbound Maximum Tolerated Dose (MTD) (10 mg or 15 mg, the max dose a participant could tolerate) experienced on average a 20.2% (50 Ibs) weight loss compared to an average of 13.7% (33 Ibs) weight loss for participants on Wegovy MTD (1.7 mg or 2.4 mg, the max dose a participant could tolerate). Average starting weights were 248.4 lbs for Zepbound MTD and 250 lbs for Wegovy MTD. Wegovy® is a registered trademark of Novo Nordisk A/S.
About LillyDirect
LillyDirect is a digital health platform designed to connect people living with chronic conditions to the care, support, and prescribed medicines they need. The platform brings together disease specific resources, access to independent healthcare providers, and convenient pharmacy services to help patients navigate their care. Prescription fulfillment through LillyDirect is open to all U.S. healthcare providers licensed to prescribe Lilly medicines and is listed as a pharmacy option in all major electronic health records (EHR) systems.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.